摘要 |
<p>The invention relates to a pharmaceutical composition containing an effective amount of ezrin mutated on tyrosin 353, or a functional fragment or derivative thereof, in association with a pharmaceutically acceptable carrier, for use preferably in the prevention and/or treatment of tumors.</p> |